Clinical Trials

Orthostatic hypotension (postural hypotension)

Displaying 2 studies

  • Droxidopa / Pyridostigmine in Orthostatic Hypotension Rochester, MN

    The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE). This combination should result in enhanced orthostatic release of NE. The investigators have already demonstrated that pyridostigmine does not raise supine blood pressure.

  • 3,4-diaminopyridine (3,4-DAP) use in Patients with Orthostatic Hypotension and Postural Tachycardia Syndrome Rochester, MN

    If the efficacy of 3,4-diaminopyridine (3,4-DAP) can be demonstrated in this study, the use of 3,4-DAP alone and in combination with other agents such as pyridostigmine and L-DOPS would be further evaluated in a double-blind randomized placebo-controlled cross-over study

.

Mayo Clinic Footer